Mitophagy in Mitochondrial Health, Dysfunction, Aging, and Disease
What Is Mitophagy and Why Does It Matter for Mitochondrial Health?
Mitophagy selectively removes mitochondria that are damaged, redundant or simply not performing, using the autophagy–lysosome system. Done well, and in step with the production of new mitochondria, it helps preserve respiratory capacity, keeps oxidative and inflammatory signalling in check, and supports resilience in energy-hungry tissues such as skeletal muscle, heart, brain, liver and kidney.¹⁻⁵ For practitioners, it offers a useful shift in perspective: mitochondrial health isn’t only about how much energy cells make, but about how well they look after the machinery that makes it.
The idea has a short but striking history. In 2005, John Lemasters proposed the term “mitophagy” for selective mitochondrial autophagy, framing it as a defence against oxidative stress, mitochondrial dysfunction and aging.⁶ Around the same time, geneticists had already tied mutations in the genes for Parkin and PINK1 to inherited Parkinson disease.⁷,⁸ Then, in 2008, Richard Youle and colleagues showed that Parkin is recruited selectively to impaired mitochondria and drives their removal.⁹ That finding connected a human disease gene directly to mitochondrial quality control.
It helps to see mitophagy as one part of a wider renewal system, alongside fission and fusion, protein quality control, lysosomal function and biogenesis. PINK1–Parkin is the best-characterised route for flagging damaged mitochondria, but receptor-mediated and basal pathways handle much of the everyday turnover in many tissues. One caveat is worth keeping in mind when reading the human literature. Most studies rely on static snapshots, such as protein levels, transcripts or tissue morphology, rather than mitophagic flux, which is the full sequence from tagging a mitochondrion to its degradation in the lysosome.¹⁻⁵
Clinically, the key principle is balance. If clearance falls short, dysfunctional mitochondria accumulate - and if clearance runs ahead of replacement, respiratory reserve wears away. A change in mitophagy can also drive, compensate for, or simply follow another disturbance, so the most informative studies measure flux in a relevant tissue, assess replacement alongside clearance, and link pathway changes to functional outcomes.¹,²
How Does Mitophagy Maintain Mitochondrial Quality Control?
Mitochondria respond continuously to changes in energy demand, nutrient availability, oxygen tension, calcium signalling, and oxidative stress, and this constant activity inevitably wears on their proteins, membranes, and genomes. Cells manage much of this damage without removing the organelle: misfolded proteins are refolded or degraded by mitochondrial proteases, and localised defects are diluted when damaged mitochondria fuse with healthy neighbours. When damage outpaces these repair systems, the affected mitochondria, or segments of them, must be isolated and removed. Mitophagy provides this selective step, linking damaged or surplus mitochondrial material to the autophagy–lysosome system.¹,⁴,⁵
Why Do Cells Need to Remove Damaged Mitochondria?
Without effective turnover, mitochondria with impaired respiration, altered membrane potential, damaged proteins, or abnormal genomes can persist, contributing to aberrant redox signalling, calcium dysregulation, inflammatory damage signals, and reduced cellular resilience. Removal is beneficial only when degradation is completed and biogenesis restores lost capacity, which is why mitophagy is best viewed as one component of mitochondrial renewal rather than an isolated disposal pathway.¹,⁴,¹⁰
Effective adaptation clears out the damaged material without draining the network. It’s easy to read raised PINK1, Parkin, LC3 or p62 as a sign that mitophagy is working well, but these markers build up both when the process is switched on and when degradation is blocked further down the line.¹,⁴
| Step | Biological purpose | Key interpretation |
|---|---|---|
| Stress sensing | Detect altered protein import, membrane potential, protein integrity, redox state, or morphology | Damage signals vary by tissue and stimulus. |
| Cargo selection | Mark mitochondria through ubiquitin signals or receptor pathways | PINK1–Parkin does not account for all physiological mitophagy. |
| Sequestration | Recruit LC3/GABARAP-positive autophagic membranes | Autophagosome formation alone does not constitute completed flux. |
| Lysosomal degradation | Deliver and degrade selected mitochondrial material | Lysosomal impairment can cause marker accumulation. |
| Renewal | Coordinate biogenesis and network remodelling | Clearance must be matched by functional replacement. |
How Does the PINK1-Parkin Pathway Identify Damaged Mitochondria?
The PINK1–Parkin pathway functions as a sensor of mitochondrial import competence. In healthy, polarised mitochondria, the kinase PINK1 is imported and rapidly degraded. When import fails, typically after loss of membrane potential, PINK1 accumulates on the outer membrane, where it phosphorylates ubiquitin and activates Parkin, an E3 ubiquitin ligase that amplifies ubiquitination of outer-membrane proteins. Autophagy receptors such as optineurin and NDP52 then link this ubiquitin coat to LC3/GABARAP proteins on the forming autophagic membrane. Because much of this understanding comes from models of acute chemical depolarisation, it may not fully reflect basal turnover or the lower-grade mitochondrial stress of human aging.³⁻⁵
What Is Receptor-Mediated Mitophagy?
A second class of mitophagy operates independently of ubiquitin labelling. Outer-membrane receptors, including BNIP3, NIX, and FUNDC1, contain LC3-interacting regions that bind autophagic membranes directly. These receptor-mediated pathways contribute to hypoxic adaptation, developmental programmes, the programmed elimination of mitochondria during erythrocyte maturation, and tissue-specific stress responses. Because their relative contribution varies with cell type and physiological context, no single marker adequately represents mitochondrial turnover.⁴,⁵
How Do Fission, Fusion, and Lysosomes Interact With Mitophagy?
Mitochondrial dynamics shape which material becomes available for degradation. Fusion permits exchange of contents and functional complementation between mitochondria, whereas fission can isolate damaged regions for repair or removal. Fission is neither synonymous with mitophagy nor inherently pathological. Selected material must subsequently reach acidified, functionally competent lysosomes for degradation to occur. These processes are coordinated by energy- and nutrient-sensing networks, including AMPK, mTOR, the sirtuins, and PGC-1α-associated transcriptional programmes, which integrate energetic stress, autophagy, and mitochondrial biogenesis.¹,⁴,⁵
How Does Exercise Influence Mitophagy and Mitochondrial Health?
Exercise provides a well-characterised human model of coordinated mitochondrial remodelling. Acute contractile activity alters ATP turnover, calcium flux, redox signalling, and mitochondrial protein stress. During recovery, autophagy-related signalling, changes in mitochondrial dynamics, and biogenesis contribute jointly to adaptation. Human skeletal muscle biopsy studies demonstrate that these pathways are responsive to training; however, direct measurement of mitophagic flux is uncommon, and findings vary with exercise modality, training status, nutritional state, and biopsy timing.¹,¹¹
For practitioners, exercise is the most accessible and best-supported means of engaging this biology, and the benchmark against which targeted interventions should be considered. It also shows that mitophagy supports physiological adaptation rather than serving only as damage disposal, and that a rise in pathway proteins alone does not confirm greater clearance or improved function.
How Can Impaired Mitophagy Contribute to Mitochondrial Dysfunction?
As a multi-stage process, mitophagy may fail at several points. Damaged mitochondria may escape recognition; autophagic membranes may not form; trafficking to, or fusion with, lysosomes may be impaired; degradation may remain incomplete; or clearance may exceed the rate of biogenesis. These distinct failures can generate similar patterns in static biomarkers. Inadequate turnover may allow dysfunctional mitochondria and pro-inflammatory damage signals to accumulate, whereas excessive or mistimed clearance may diminish mitochondrial content and respiratory reserve.¹,²,¹⁰,¹²,¹³
Increased mitophagy should therefore not be regarded as uniformly beneficial. Cancer illustrates this point: mitochondrial clearance may limit cellular damage during early transformation, yet may also support the survival of established tumour cells under metabolic stress. The net effect is determined by tissue type, timing, disease stage, and the specific pathway engaged.²,¹²
Which Aging and Disease-Related States Are Associated With Mitophagy?
Since PINK1 and Parkin were linked to familial Parkinson disease, altered mitophagy has been reported across neurodegenerative, cardiometabolic, renal, hepatic, musculoskeletal, and oncological conditions. The strength of human evidence varies widely, and in most cases it remains unclear whether altered mitophagy is causal, compensatory, or secondary.
| Health or disease area | Human evidence | Current interpretation |
|---|---|---|
| Healthy aging and skeletal muscle | Exercise biopsies and randomised trials of urolithin A | Mitochondrial quality-control pathways are modifiable, but direct mediation by mitophagy remains uncertain.1,14–16 |
| Parkinson disease | Human genetics and patient-derived cells | PINK1 and PRKN variants provide the strongest causal human link; familial disease does not represent all sporadic Parkinson disease.3,13 |
| Alzheimer disease and dementia | Post-mortem, biomarker, and patient-derived evidence | Altered mitochondrial and lysosomal pathways are reported, but temporal sequence and therapeutic causality are uncertain.2,13 |
| Cardiovascular disease and heart failure | Human myocardium, blood cells, and iPSC-derived cardiomyocytes | Human relevance is supported; evidence for treatments directly targeting mitophagy remains early.2,17 |
| Type 2 diabetes and complications | Human tissue and observational evidence | Mitophagy is implicated in metabolic tissues, but most causal evidence remains preclinical.2,18 |
| Liver and kidney disease | Human tissue and translational evidence | Pathway changes are reported across several conditions; validated clinical target-engagement evidence is limited.2,10 |
| Osteoarthritis | Primary human chondrocytes and animal intervention data | Ex vivo human findings do not establish efficacy in people with osteoarthritis.19 |
| Cancer | Human tumour associations and experimental models | Effects are bidirectional and dependent on tumour context.2,12 |
How Is Mitophagy Measured in Human Research?
No single assay captures mitophagy in its entirety. Each measure reflects one stage of the process, so the conclusions a study can draw depend on which measures it combines.
| Health or disease area | Human evidence | Current interpretation |
|---|---|---|
| Healthy aging and skeletal muscle | Exercise biopsies and randomised trials of urolithin A | Mitochondrial quality-control pathways are modifiable, but direct mediation by mitophagy remains uncertain.1,14–16 |
| Parkinson disease | Human genetics and patient-derived cells | PINK1 and PRKN variants provide the strongest causal human link; familial disease does not represent all sporadic Parkinson disease.3,13 |
| Alzheimer disease and dementia | Post-mortem, biomarker, and patient-derived evidence | Altered mitochondrial and lysosomal pathways are reported, but temporal sequence and therapeutic causality are uncertain.2,13 |
| Cardiovascular disease and heart failure | Human myocardium, blood cells, and iPSC-derived cardiomyocytes | Human relevance is supported; evidence for treatments directly targeting mitophagy remains early.2,17 |
| Type 2 diabetes and complications | Human tissue and observational evidence | Mitophagy is implicated in metabolic tissues, but most causal evidence remains preclinical.2,18 |
| Liver and kidney disease | Human tissue and translational evidence | Pathway changes are reported across several conditions; validated clinical target-engagement evidence is limited.2,10 |
| Osteoarthritis | Primary human chondrocytes and animal intervention data | Ex vivo human findings do not establish efficacy in people with osteoarthritis.19 |
| Cancer | Human tumour associations and experimental models | Effects are bidirectional and dependent on tumour context.2,12 |
A single protein, transcript, or image is one time point in a dynamic pathway. Increased PINK1, Parkin, LC3, p62, BNIP3, or NIX may reflect greater initiation, compensatory activation, or stalled degradation, which a single measurement cannot distinguish. Robust studies therefore combine pathway markers with lysosomal inhibition or reporter methods, measures of mitochondrial content and respiration, and a relevant tissue-level outcome.¹,⁴
What Does the Human Evidence Show About Mitophagy?
Mitophagy contributes to the regulation of mitochondrial quality and quantity and depends on intact autophagic and lysosomal systems. PINK1–Parkin is a validated damage-response mechanism, although it does not account for all basal or tissue-specific turnover. The most direct evidence linking mitophagy to human disease is genetic: pathogenic variants in PINK1 and PRKN cause familial Parkinson disease. Exercise studies further demonstrate that mitochondrial quality-control signalling is adaptable in humans.¹⁻⁵,¹¹,¹³ No validated, minimally invasive biomarker yet quantifies whole-body or organ-specific mitophagic flux, and it remains unresolved whether mitophagy declines globally with age or becomes dysregulated in tissue-specific ways. So-called mitophagy activators may also act on general autophagy, lysosomal function, inflammation, redox state, or biogenesis, and target engagement alone does not establish clinical benefit.¹,²,¹²
What Do Urolithin A Trials Show About Mitophagy?
Direct intervention evidence centres on aging skeletal muscle and urolithin A, a gut microbial metabolite of dietary ellagitannins. Trials in older and middle-aged adults support molecular target engagement, including changes in mitophagy-related proteins, plasma acylcarnitines, and mitochondrial gene expression, alongside possible improvements in endurance and strength. However, several primary endpoints were not met, and mediation by mitophagy has not been demonstrated.¹⁴⁻¹⁶
Can Lifestyle or Nutritional Interventions Support Mitophagy?
Physical activity, energy balance, and periods of inactivity all shape the energetic and oxidative signals that govern mitochondrial turnover, and a small number of targeted compounds have been investigated for their effects on mitochondrial quality control. Direct human evidence that these factors change mitophagic flux remains limited, so their use is best guided by the overall strength of human evidence, with exercise as the foundation for any targeted nutritional approach.
| Factor | Potential relationship to mitophagy | Evidence boundary |
|---|---|---|
| Exercise | Coordinates energetic signalling, turnover, dynamics, and biogenesis | Strong physiological relevance; direct human flux is rarely measured.11 |
| Fasting or energy-restriction paradigms | May engage AMPK, mTOR, and autophagic pathways | Human evidence is context-specific and does not justify presenting fasting as a mitophagy treatment. |
| Aging, inactivity, and metabolic stress | May alter damage burden, lysosomal capacity, and adaptation | Direction differs by tissue and may be causal, compensatory, or secondary.1,2 |
| Urolithin A | Developed around mitophagy biology and tested in aging and muscle trials | Molecular changes do not prove that mitophagy mediated functional outcomes.14–16,19 |
| Mitoquinol | Mitochondria-targeted redox compound relevant to damage burden and quality-control signalling20 | Direct evidence of increased mitophagic flux in humans has not been established. |
How Is Mitoquinol Relevant to Mitophagy and Mitochondrial Dysfunction?
Mitoquinol (MitoQ) is a ubiquinol derivative conjugated to a lipophilic triphenylphosphonium cation, which drives its accumulation within mitochondria, where it participates in redox cycling. Because mitochondrial reactive oxygen species, membrane potential, fragmentation, and damage burden all influence how mitochondria are recognised by quality-control pathways, mitoquinol has been investigated in several preclinical models in which mitochondrial oxidative stress coexists with altered mitophagy. These studies show that it can modulate mitophagy-related pathways under defined conditions, without establishing it as a universal or direct mitophagy activator.²⁰⁻²⁴
What Do Preclinical Studies Show About MitoQ and Mitophagy?
The effects of mitoquinol on mitophagy are context dependent. Where mitophagy was impaired, mitoquinol restored mitophagy-related signalling. In diabetic kidney disease, it reduced mitochondrial oxidative stress and fragmentation and partially restored PINK1 and Parkin expression through an Nrf2/PINK1-associated mechanism; blocking Nrf2 or PINK1 partly abolished these protective effects.²¹ In a rat model of myocardial ischaemia–reperfusion injury with type 2 diabetes, mitoquinol enhanced PINK1/Parkin-associated mitophagy while reducing oxidative stress, cardiomyocyte apoptosis, and cardiac dysfunction, and inhibiting mitophagy weakened this protection.²²
In other settings, mitoquinol dampened rather than enhanced mitophagy-related signalling. In vascular smooth muscle cells and mouse aorta exposed to fine particulate matter (PM2.5), oxidative stress was accompanied by fragmentation and raised PINK1, Parkin, LC3-II/I, and p62. Mitoquinol lowered these markers while improving membrane potential, respiration, ATP production, and vascular fibrosis, consistent with removing the damage signals that drive excessive quality-control activity rather than stimulating further clearance.²³ Related reductions in mitochondrial oxidative stress have been reported in cigarette smoke-exposed lung epithelial cells and in a mouse model of Kawasaki disease vasculitis, both characterised by impaired autophagy and mitophagy.²⁴,²⁵
Together, these findings suggest that mitoquinol may normalise mitochondrial quality control by modifying the redox and damage environment, restoring insufficient PINK1/Parkin signalling in some models and attenuating stress-induced mitophagy in others. Most studies relied on pathway proteins, mitochondrial function, and tissue outcomes rather than complete flux measurements, and human mitoquinol studies of oxidative stress, vascular function, or bioenergetics should not be reinterpreted as direct evidence of mitophagy.
Key next steps are to test whether mitoquinol alters complete mitophagic flux in defined human tissues, and whether any effect depends on baseline oxidative stress, tissue type, or the nature of the mitochondrial insult. Such studies should pair flux measurements with respiration, mitochondrial content, and clinically meaningful outcomes, and distinguish stimulation of clearance from reduction of the damage that triggers it. On current evidence, mitoquinol has demonstrated context-dependent, mitophagy-modulating effects in preclinical models; direct effects on human mitophagy remain to be established.
Key Takeaways
In less than two decades, mitophagy has moved from a proposed defence mechanism to a validated pathway with direct genetic links to human disease.
Mitophagy is the selective turnover of mitochondria and a core component of mitochondrial quality control, integrated with dynamics, lysosomal function, and biogenesis.
PINK1–Parkin is the best-characterised pathway, but receptor-mediated and basal mechanisms also contribute to mitochondrial renewal.
Impaired, excessive, or mistimed mitophagy may each contribute to mitochondrial dysfunction, depending on tissue and disease context.
Human evidence is strongest in genetics, exercise physiology, skeletal muscle, and urolithin A research; direct intervention evidence in disease remains limited.
No single static biomarker establishes mitophagic flux or clinical benefit.
Mitoquinol is relevant to mitochondrial redox and quality-control research and has shown context-dependent effects on mitophagy in preclinical models; direct activation of human mitophagy has not been established.
References
Picca A, et al. Mitophagy in human health, ageing and disease. Nature Metabolism. 2023;5:2047-2061. doi:10.1038/s42255-023-00930-8.
Wang Q, et al. Mitophagy in the pathogenesis and management of disease. Cell Research. 2026;36:11-37. doi:10.1038/s41422-025-01203-7.
Narendra DP, Youle RJ. The role of PINK1-Parkin in mitochondrial quality control. Nature Cell Biology. 2024;26:1639-1651. doi:10.1038/s41556-024-01513-9.
Killackey SA, et al. Mitophagy pathways in health and disease. Journal of Cell Biology. 2020;219:e202004029. doi:10.1083/jcb.202004029.
Onishi M, et al. Molecular mechanisms and physiological functions of mitophagy. EMBO Journal. 2021;40:e104705. doi:10.15252/embj.2020104705.
Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Research. 2005;8:3-5. doi:10.1089/rej.2005.8.3.
Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-608. doi:10.1038/33416.
Valente EM, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158-1160. doi:10.1126/science.1096284.
Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Journal of Cell Biology. 2008;183:795-803. doi:10.1083/jcb.200809125.
Doblado L, et al. Mitophagy in human diseases. International Journal of Molecular Sciences. 2021;22:3903. doi:10.3390/ijms22083903.
Tang S, et al. The role of mitophagy in metabolic diseases and its exercise intervention. Frontiers in Physiology. 2024;15:1339128. doi:10.3389/fphys.2024.1339128.
Wang S, et al. The mitophagy pathway and its implications in human diseases. Signal Transduction and Targeted Therapy. 2023;8:304. doi:10.1038/s41392-023-01503-7.
Antico O, et al. Targeting mitophagy in neurodegenerative diseases. Nature Reviews Drug Discovery. 2025;24:276-299. doi:10.1038/s41573-024-01105-0.
Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1:595-603. doi:10.1038/s42255-019-0073-4.
Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults. JAMA Network Open. 2022;5:e2144279. doi:10.1001/jamanetworkopen.2021.44279.
Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health. Cell Reports Medicine. 2022;3:100633. doi:10.1016/j.xcrm.2022.100633.
Yang M, et al. Assessment of mitophagy in human iPSC-derived cardiomyocytes. Autophagy. 2022;18:2481-2494. doi:10.1080/15548627.2022.2037920.
Apostolova N, et al. Mitochondrial dysfunction and mitophagy in type 2 diabetes. Antioxidants & Redox Signaling. 2023;39:278-320. doi:10.1089/ars.2022.0016.
D’Amico D, et al. Urolithin A improves mitochondrial health in osteoarthritis models. Aging Cell. 2022;21:e13662. doi:10.1111/acel.13662.
Sun C, et al. MitoQ regulates autophagy by inducing a pseudo-mitochondrial membrane potential. Autophagy. 2017;13:730-738. doi:10.1080/15548627.2017.1280219.